PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
3.86%
Operating income growth of 3.86% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
-1.47%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
12.77%
EPS growth of 12.77% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
13.49%
Diluted EPS growth of 13.49% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
16.41%
Share change of 16.41% while Biotechnology median is zero. Walter Schloss would see if the modest difference matters long-term.
17.29%
Diluted share change of 17.29% while Biotechnology median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
23.86%
OCF growth of 23.86% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
23.57%
FCF growth of 23.57% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-19211.55%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-43.46%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-15978.83%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-50766.69%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
48.21%
3Y net income/share CAGR of 48.21% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
19776.75%
Equity/share CAGR of 19776.75% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
4394.26%
5Y equity/share CAGR of 4394.26% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
625.15%
3Y equity/share CAGR of 625.15% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Asset growth of 30.51% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
8.68%
Positive BV/share change while Biotechnology median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
108.24%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.